Istradefylline effective adjunct therapy for Parkinson's disease

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1588, 2007-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Istradefylline for the treatment of Parkinson's disease

By Park Ariane Stacy Mark

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite

Transdermal rotigotine effective adjunct in Parkinson's disease

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite

Safinamide an appealing adjunct in Parkinson's disease

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite